Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with 99mTc

Breast Cancer Research and Treatment

Volumn 96, Issue 2, 2006, Pages 115-121

  Oliva, Juan P ^a   Valdés, Zodilina ^a   Casacó, Angel ^b   Pimentel, Gilmara ^a   González, Joaquín ^a   Álvarez, Irene ^a   Osorio, Martha ^a   Velazco, Milagros ^a   Figueroa, Mariela ^c   Ortiz, Rosa ^a   Escobar, Xiomara ^a   Orozco, Maiby ^a   Cruz, Julia ^a   Franco, Sonia ^a   Díaz, Mirtha ^a   Roque, Lourdes ^b   Carr, Adriana ^b   Vázquez, Ana M ^b   Mateos, Cristina ^b   Rubio, María C ^a   Pérez, Rolando ^b   Fernández, Luis E ^b   more..

^a INSTITUTO NACIONAL DE ONCOLOGÍA Y RADIOBIOLOGÍA   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c Hospital Luis Diaz Soto   (Cuba)

Author keywords

Breast cancer; Breast immunoscintigraphy; GM3(NeuGc) ganglioside; Monoclonal antibody; Radioimmunodiagnosis

Indexed keywords

ANTIBODY CONJUGATE; GANGLIOSIDE GM3; MONOCLONAL ANTIBODY 14F7 TC 99M; RADIOISOTOPE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG UPTAKE; FEMALE; HUMAN; IMMUNOSCINTIGRAPHY; IN VIVO STUDY; INJECTION; ISOTOPE LABELING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; G(M3) GANGLIOSIDE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOIMMUNODETECTION; TECHNETIUM;

EID: 33645237406     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9064-0     Document Type: Article

References (28)

1. Hougton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ: Mouse monoclonal antibody IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82: 1242-1246, 1985
2. Zhang S, Cordon Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO: Selection of carbohydrate tumour antigens as targets for immune attack using immunohisto-chemistry. I. Focus on gangliosides. Int J Cancer 73: 42-49, 1997
3. Stults CLM, Sweeley CC, Matcher BA: Glycosphingolipids: structure, biological source, and properties. Methods Enzymol 179: 167-214, 1989
4. Hakomori SH: Possible functions of tumour-associated carbohydrate antigens. Curr Opin Immunol 3: 646-653, 1991
5. Corfield AP, Schauer R: Occurrence of sialic acids. Cell Biol Monogr 10: 5-50, 1982
6. Leeden RW, Yu RK: Chemistry and analysis of sialic acid. In: Rosemberg A, Schengtrund CL (eds) Biological Role of Sialic Acid. Plenum, New York 1976, pp 1-48
7. Kawai T, Kato A, Higashi H, Kato S, Naiki M: Quantitative determination of N glycolylneuraminic acid expression in human cancerous tissues and avian lymphoma cell lines as a tumour-associated sialic acid by gas chromatography-mass spectometry. Cancer Res 51: 1242-1246, 1991
8. Higashi H, Sasabe T, Fukui Y, Maru M. Kato S: Detection of gangliosides as N-glycolylneuraminic acid-specific tumour-associated Hanganutziu-Deicher antigen in human retinoblastoma cells. Jpn J Cancer Res 79: 952-956, 1988
9. Fukui Y, Maru M, Ohkawara KI, Miyake T, Osada Y, Wang D, Ito T, Higashi H, Naiki M, Wakamiya N, Kato S: Detection of glycoproteins as tumour-associated Hanganutziu-Deicher antigen in human gastric cancer cell line, NUGC4. Biochem Biophys Res Commun 160: 1149-1154, 1989
10. Koda T, Shimosakoda T, Asaoka H, Nishinaka S, Tamura I, Nakaba H, Matsuda H: Detection of the Hanganutziu-Deicher antigen in patients with hepatocellular carcinoma. Int Hepatol Commun 2: 310-315, 1994
11. Furukawa K, Yamaguchi H, Oettgen HF, Old LJ, Lloyd KO: Analysis of the expression of N-glycolylneuraminic acid-containing gangliosides in cell and tissues using two human monoclonal antibodies. J Biol Chem 263: 18507-18512, 1988
12. Miyake M, Hashimoto K, Ito M, Ogawa O, Arai E, Hitomi S, Kannagi R: The abnormal occurrence and the differentiation-dependent distribution of N-acetyl and N-glycolyl species of the ganglioside GM2 in human germ cell tumours. A study with specific monoclonal antibodies. Cancer 65: 499-505, 1990
13. Marquina G, Waki H, Fernández LE, Kon K, Carr A, Valiente O, Pérez R, Ando S: Gangliosides expressed in human breast cancer. Cancer Res 56: 5165-5171, 1996
14. Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, Rengifo E, Pérez R, Fernández LE: A mouse IgG1 monoclonal antibody specific for N-Glycolyl GM3 ganglioside recognized breast and melanoma tumours. Hybridoma 19: 241-247, 2000
15. Carr A, Mesa C, Arango M, Vázquez AM, Fernández LE: "In vivo" and "in vitro" anti-tumour effect of 14F7 monoclonal antibody. Hybridoma and Hybridomics 21: 463-468, 2002
16. Mather JS, Ellison D: Reduction-mediated technetium-99 m labeling of monoclonal antibodies. J Nucl Med 31: 692-697, 1990
17. Hsu SM, Raine L, Fanger H: Use the avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabelled antibody PAP procedures. J Histochem Cytochem 29: 577-580, 1989
18. American Cancer Society. Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society, 2004. tttp://www.cancer.org/docroot/STT/stt_O.asp
19. Hakomori S: Aberrant glycosylation in cancer cell membranes as focused on glycolipids: Overview and perperstive. Cancer Res 45: 2405-2414, 1985
20. Plalet N, Cathiard AM, Gleizes M, Garcia M: Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51: 55-67, 2004
21. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791-808, 1998
22. Sharma AK, Horgan K, Douglas-Jones A, McClelland R, Gee J, Nicholson R: Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 69: 1032-1037, 1994
23. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM: Modulation of epidermal growth factor receptor in endocrine resistant, oestrogen receptor-positive breast cancer. Endcr Relat Cancer 8: 175-182, 2001
24. Estevez F, Carr A, Solarzano L, Valiente O, Mesa C, Barroso O, Sierra G, Fernandez LE: Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 18: 190-197, 1999
25. Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE: Cancer vaccines: An update with special focus on ganglioside antigens (Review). Oncol Reports 9: 267-276, 2002
26. Carr A, Rodriguez E, Arango M, Camacho R, Osorio M, Gabri M, Carrillo G, Valdes Z, Bebelagua Y, Perez R, Fernandez LE: Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J Clin Oncol 21: 1015-1021, 2003
27. Fernández LE, Alonso DF, Gómez DE, Vázquez AM: Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Exprt Rev Vaccines 2: 89-95, 2003
28. Mesa C, León J, Rigley K, Fernández LE: Very small proteoliposomes derived from Neisseria meningitides: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 22: 3045-3052, 2004